Gonçalo Moniz Institute, Oswaldo Cruz Foundation (IGM-FIOCRUZ/BA), Salvador, Brazil.
Department of Pathology and Forensic Medicine, School of Medicine, Federal University of Bahia, Salvador, Brazil.
PLoS One. 2022 Jul 7;17(7):e0271002. doi: 10.1371/journal.pone.0271002. eCollection 2022.
Drug repurposing has been applied in the biomedical field to optimize the use of existing drugs, leading to a more efficient allocation of research resources. In oncology, this approach is particularly interesting, considering the high cost related to the discovery of new drugs with therapeutic potential. Computational methods have been applied to predict associations between drugs and their targets. However, drug repurposing has not always been promising and its efficiency has yet to be proven. Therefore, the present scoping review protocol was developed to screen the literature on how in silico strategies can be implemented in drug repurposing in oncology. The scoping review will be conducted according to the Arksey and O'Malley framework (2005) and the Joanna Briggs Institute recommendations. We will search the PubMed/MEDLINE, Embase, Scopus, and Web of Science databases, as well as the grey literature. We will include peer-reviewed research articles involving in silico strategies applied to drug repurposing in oncology, published between January 1, 2003, and December 31, 2021. Data will be charted and findings described according to review questions. We will report the scoping review using the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Review guidelines (PRISMA-ScR).
药物重定位已应用于生物医学领域，以优化现有药物的使用，从而更有效地分配研究资源。在肿瘤学领域，这种方法尤其有趣，因为与发现具有治疗潜力的新药相关的成本很高。已经应用计算方法来预测药物与其靶点之间的关联。然而，药物重定位并不总是有希望的，其效率还有待证明。因此，制定了本范围综述方案，以筛选关于计算策略如何在肿瘤学中的药物重定位中实施的文献。范围综述将根据 Arksey 和 O'Malley 框架（2005 年）和 Joanna Briggs 研究所的建议进行。我们将搜索 PubMed/MEDLINE、Embase、Scopus 和 Web of Science 数据库以及灰色文献。我们将包括涉及在肿瘤学中应用于药物重定位的计算策略的同行评审研究文章，发表时间为 2003 年 1 月 1 日至 2021 年 12 月 31 日。将根据审查问题对数据进行图表绘制和结果描述。我们将使用系统评价和荟萃分析扩展的首选报告项目（PRISMA-ScR）报告范围综述。
